nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Author index
|
|
|
2005 |
49 |
S3 |
p. S99-S100 2 p. |
artikel |
2 |
E59. Advances in endoscopic diagnosis and treatment
|
Sutedja, Thomas G. |
|
2005 |
49 |
S3 |
p. S91- 1 p. |
artikel |
3 |
E32. Advances in endoscopic diagnosis of early lesions of the bronchus
|
Ikeda, N. |
|
2005 |
49 |
S3 |
p. S52-S53 2 p. |
artikel |
4 |
E19. Arterial sleeve resection
|
Dieneman, Hendrik |
|
2005 |
49 |
S3 |
p. S30- 1 p. |
artikel |
5 |
E29. Biomarker-integrated targeted therapeutic trials
|
Hong, Waun Ki |
|
2005 |
49 |
S3 |
p. S49- 1 p. |
artikel |
6 |
E8. Bronchoscopic biopsy of isolated, peripheral lung lesions underendobronchial ultrasound (EBUS) and electromagnetic guidance
|
Becker, Heinrich D. |
|
2005 |
49 |
S3 |
p. S12-S13 2 p. |
artikel |
7 |
E21. Carboplatin versus cisplatin in lung cancer
|
Einhorn, Lawrence H. |
|
2005 |
49 |
S3 |
p. S32-S35 4 p. |
artikel |
8 |
E28. Chemoprevention of lung cancer: Intermediate endpoints for chemoprevention trials
|
Hirsch, Fred R. |
|
2005 |
49 |
S3 |
p. S47-S48 2 p. |
artikel |
9 |
E25. Chemotherapy in elderly patients
|
Gridelli, Cesue |
|
2005 |
49 |
S3 |
p. S42-S43 2 p. |
artikel |
10 |
E46. Clinical and biological implications of epidermal growth factor receptor (EGFR) gene mutations and gefitinib treatment for NSCLC
|
Mitsudomi, Tetsuya |
|
2005 |
49 |
S3 |
p. S76- 1 p. |
artikel |
11 |
E44. Clinical research in lung cancer is inefficient and often irrelevant: For
|
Macbeth, Fergus |
|
2005 |
49 |
S3 |
p. S73- 1 p. |
artikel |
12 |
E2. Current research in lung cancer is inefficient and usually irrelevant: For
|
Arriagada, Rodrigo |
|
2005 |
49 |
S3 |
p. S3-S4 2 p. |
artikel |
13 |
E16. 4D CT (Computed Tomography) improves TCP without an increase in NTCP of lung when compared with helical CT planning in 3D conformal radiation therapy (CRT) for patients with lung cancer
|
Choi, Noah C. |
|
2005 |
49 |
S3 |
p. S25-S26 2 p. |
artikel |
14 |
E41. Dilemmas in management: The controversial role of chemotherapy in PS 2 advanced NSCLC
|
Langer, Corey J. |
|
2005 |
49 |
S3 |
p. S64-S68 5 p. |
artikel |
15 |
E26. Early stage peripheral lesion
|
Herth, Felix J.F. |
|
2005 |
49 |
S3 |
p. S44-S45 2 p. |
artikel |
16 |
E39. Endoscopic detection and markers of early lung cancer
|
Lam, Stephen |
|
2005 |
49 |
S3 |
p. S62- 1 p. |
artikel |
17 |
E56. EORTC recommendations for treatment planning and execution in lung cancer: An update
|
Senan, Suresh |
|
2005 |
49 |
S3 |
p. S88- 1 p. |
artikel |
18 |
E57. Estrogen receptor epidermal growth factor receptor interactions in lung cancer
|
Siegfried, Jill M. |
|
2005 |
49 |
S3 |
p. S89- 1 p. |
artikel |
19 |
E9. Expression profiling of lung cancer and its clinical implications
|
Beer, David G. |
|
2005 |
49 |
S3 |
p. S14-S15 2 p. |
artikel |
20 |
E40. Genetic alterations in pre-invasive lung cancer
|
Lam, Stephen |
|
2005 |
49 |
S3 |
p. S63- 1 p. |
artikel |
21 |
E42. Global perspectives on lung cancer. Asian perspectives
|
Soo Lee, Jin |
|
2005 |
49 |
S3 |
p. S69-S70 2 p. |
artikel |
22 |
E12. IASLC: Think globally, act locally
|
Bunn Jr., Paul A. |
|
2005 |
49 |
S3 |
p. S20- 1 p. |
artikel |
23 |
E13. Identification of genomic changes associated with resistanceto standard chemotherapy in a xenograft model of human NSCLC
|
Buys, Timon P.H. |
|
2005 |
49 |
S3 |
p. S21- 1 p. |
artikel |
24 |
E51. Impact of molecular tools in lung cancer pathology: Impact of molecular studies on lung tumor classification
|
Petersen, Iver |
|
2005 |
49 |
S3 |
p. S81- 1 p. |
artikel |
25 |
E1. Improving cancer management with reference to resources
|
Abratt, Raymond P. |
|
2005 |
49 |
S3 |
p. S1-S2 2 p. |
artikel |
26 |
E35. Infections in lung cancer
|
Klastersky, Jean |
|
2005 |
49 |
S3 |
p. S57- 1 p. |
artikel |
27 |
E3. Lung cancer in Latin America: A perspective
|
Arriagada, Rodrigo |
|
2005 |
49 |
S3 |
p. S5-S6 2 p. |
artikel |
28 |
E30. Lung premalignancy and chemoprevention
|
Hong, Waun Ki |
|
2005 |
49 |
S3 |
p. S50- 1 p. |
artikel |
29 |
E15. Malignant mesothelioma
|
Carbone, Michele |
|
2005 |
49 |
S3 |
p. S24- 1 p. |
artikel |
30 |
E38. Molecular predictors of outcome for lung cancer
|
Kratzke, Robert A. |
|
2005 |
49 |
S3 |
p. S60-S61 2 p. |
artikel |
31 |
E17. New statistical methods in translational research and targeted therapy trials
|
Crowley, John |
|
2005 |
49 |
S3 |
p. S27- 1 p. |
artikel |
32 |
E11. New targets and new agents on the horizon for lung cancer therapy
|
Bunn Jr., Paul A. |
|
2005 |
49 |
S3 |
p. S18-S19 2 p. |
artikel |
33 |
E37. Non-platinum regimens for advanced disease: Patient selection based on subhistologies of NSCLC
|
Kosmidis, Paris A. |
|
2005 |
49 |
S3 |
p. S59- 1 p. |
artikel |
34 |
E14. Optimization of thoracic irradiation: An overview
|
Byhardt, Roger W. |
|
2005 |
49 |
S3 |
p. S22-S23 2 p. |
artikel |
35 |
E47. Optimizing radiotherapy techniques for localized NSCLC
|
Mornex, Françoise |
|
2005 |
49 |
S3 |
p. S77- 1 p. |
artikel |
36 |
E50. Pain management challenges in lung cancer
|
Paice, Judith A. |
|
2005 |
49 |
S3 |
p. S80- 1 p. |
artikel |
37 |
E61. PET scan: Current recommendations and innovation
|
Vansteenkiste, Johan |
|
2005 |
49 |
S3 |
p. S94-S96 3 p. |
artikel |
38 |
E33. Pet scanning for evaluation of solitary pulmonary nodule and staging of NSCLC
|
Jett, James R. |
|
2005 |
49 |
S3 |
p. S54-S55 2 p. |
artikel |
39 |
E43. Pharmacogenomic and molecular basis for responsivenessto present combination chemotheraphy with or without targeted agents
|
Lynch, Thomas |
|
2005 |
49 |
S3 |
p. S71-S72 2 p. |
artikel |
40 |
E58. Phase I trials: The European experience
|
Soria, Jean-Charles |
|
2005 |
49 |
S3 |
p. S90- 1 p. |
artikel |
41 |
E53. Preclinical and clinical studies of molecular target-based drugs in Japan
|
Saijo, Nagahiro |
|
2005 |
49 |
S3 |
p. S84- 1 p. |
artikel |
42 |
E22. Reimbursement policies, research andprescribing practices: The Canadian perspective
|
Evans, W.K. |
|
2005 |
49 |
S3 |
p. S36-S37 2 p. |
artikel |
43 |
E20. Reimbursement policies, research, and prescribing practices: The United States perspective
|
Earle, Craig C. |
|
2005 |
49 |
S3 |
p. S31- 1 p. |
artikel |
44 |
E23. Report of the Spanish Neuroendocrine Lung Tumors Registry
|
García-Yuste, Mariano |
|
2005 |
49 |
S3 |
p. S38-S39 2 p. |
artikel |
45 |
E34. Respiratory gated and four-dimensional tumor tracking radiotherapy
|
Keall, Paul |
|
2005 |
49 |
S3 |
p. S56- 1 p. |
artikel |
46 |
E60. Restaging after induction therapy
|
Van Schil, Paul |
|
2005 |
49 |
S3 |
p. S92-S93 2 p. |
artikel |
47 |
E52. Restaging after induction treatment: Surgical techniques
|
Rami-Porta, Ramón |
|
2005 |
49 |
S3 |
p. S82-S83 2 p. |
artikel |
48 |
E45. Role of PET-CT in the optimization of thoracic radiotherapy
|
MacManus, Michael |
|
2005 |
49 |
S3 |
p. S74-S75 2 p. |
artikel |
49 |
E49. Stereotactic hypofractionated high-dose irradiation (STI) for stage I non-small cell lung cancer: Clinical outcomes in 298 cases of a Japanese multi-institutional study
|
Onishi, Hiroshi |
|
2005 |
49 |
S3 |
p. S79- 1 p. |
artikel |
50 |
E55. Study design issues and early stage non-small cell lung cancer
|
Schiller, Joan H. |
|
2005 |
49 |
S3 |
p. S87- 1 p. |
artikel |
51 |
E31. Surgery and adjuvant chemotherapy: The Japanese experience
|
Ichinose, Yukito |
|
2005 |
49 |
S3 |
p. S51- 1 p. |
artikel |
52 |
E48. Systematic lymph node dissection
|
Naruke, Tsuguo |
|
2005 |
49 |
S3 |
p. S78- 1 p. |
artikel |
53 |
E5. The degree of malignancy of neuroendocrine tumors of the lung: A Japanese registry study
|
Asamura, Hisao |
|
2005 |
49 |
S3 |
p. S8- 1 p. |
artikel |
54 |
E24. The IASLC Staging Project: an overview of progress to date
|
Goldstraw, Peter |
|
2005 |
49 |
S3 |
p. S40-S41 2 p. |
artikel |
55 |
E6. The IASLC staging project: A surgeon's perspective
|
Asamura, Hisao |
|
2005 |
49 |
S3 |
p. S9- 1 p. |
artikel |
56 |
E7. The IASLC staging project: non-small cell lung cancer: a radiation oncologist's perspective
|
Ball, David L. |
|
2005 |
49 |
S3 |
p. S10-S11 2 p. |
artikel |
57 |
E10. The investigation of bronchial epithelia from lung cancer patients: A better way of understanding lung cancer biology
|
Betticher, Daniel C. |
|
2005 |
49 |
S3 |
p. S16-S17 2 p. |
artikel |
58 |
E62. There is no rule for surgery in stage IIIaN2 or IIIb NSCLC
|
Van Houtte, Paul |
|
2005 |
49 |
S3 |
p. S97- 1 p. |
artikel |
59 |
E27. The role of fluorescence in situ hybridization as a predictive“marker” for sensitivity to EGFR inhibitors in patients with NSCLC
|
Hirsch, Fred R. |
|
2005 |
49 |
S3 |
p. S46- 1 p. |
artikel |
60 |
E36. The role of radiation therapy in themanagement of Superior Sulcus Tumors (SST)
|
Komaki, Ritsuko |
|
2005 |
49 |
S3 |
p. S58- 1 p. |
artikel |
61 |
E4. The surgical approach to early peripheral NSCLC
|
Asamura, Hisao |
|
2005 |
49 |
S3 |
p. S7- 1 p. |
artikel |
62 |
E18. Thoracoscopic lobectomy (syllabus)
|
D'Amico, Thomas |
|
2005 |
49 |
S3 |
p. S28-S29 2 p. |
artikel |
63 |
E54. Tumor suppressor pathways in lung cancer: A genomic and genetic approach
|
Sanchez-Cespedes, Montserrat |
|
2005 |
49 |
S3 |
p. S85-S86 2 p. |
artikel |